Highlights
- •Patients with APS may face permanent damage in various organs.
- •Patients with secondary APS had the highest levels of DIAPS.
- •DIAPS correlated both with risk stratification scores and with QoL questionnaires.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).J Thromb Haemost. 2006; 4: 295-306
- Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome.J Rheumatol J Rheumatol. 2012; 39: 516-523
- Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).Lupus. 2015; 24: 927-934
- The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.Arthritis Rheum. 1996; 39: 363-369
- GAPSS: the global anti-phospholipid syndrome score.Rheumatology (Oxford). 2013; 52: 1397-1403
- A 12-item short-form health survey of scales and preliminary construction tests of reliability and validity.Construction. 2015; 34: 220-233
- Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.Ann Rheum Dis. 2015;
- Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.Lupus. 2020; 29: 256-262
- Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36.Lupus. 2015; 24: 174-179
- Impairment of quality of life in patients with antiphospholipid syndrome.Lupus. 2015; 24: 1161-1168
Article info
Publication history
Published online: July 27, 2021
Accepted:
July 2,
2021
Received in revised form:
June 29,
2021
Received:
April 29,
2021
Footnotes
This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
